H.C. Wainwright Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $25

H.C. Wainwright analyst Douglas Tsao maintains $Sage Therapeutics(SAGE.US)$ with a hold rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of 37.8

Moomoo NewsJul 2 12:31 ET · Ratings

SAGE Therapeutics: A Balanced Hold Rating Amidst Promising Zurzuvae Launch and Clinical Pipeline Prospects

TipRanksJul 2 11:45 ET

Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew rec

Simply Wall StJun 22 09:24 ET

19 Analysts Have This To Say About Sage Therapeutics

Across the recent three months, 19 analysts have shared their insights on Sage Therapeutics (NASDAQ:SAGE), expressing a variety of opinions spanning from bullish to bearish.The following table provide

BenzingaJun 20 10:00 ET

J.P. Morgan Maintains Sage Therapeutics(SAGE.US) With Buy Rating, Cuts Target Price to $23

J.P. Morgan analyst Anupam Rama maintains $Sage Therapeutics(SAGE.US)$ with a buy rating, and adjusts the target price from $28 to $23.According to TipRanks data, the analyst has a success rate of 43.

moomoo NewsJun 20 09:33 ET · Ratings

Sage Therapeutics Is Maintained at Overweight by JP Morgan

Sage Therapeutics Is Maintained at Overweight by JP Morgan

Dow JonesJun 20 09:26 ET